

J. Timothy Meigs
Sector Patent Counsel

Genetic Therapy, Inc.
9 West Watkins Mill Road
Gaithersburg, MD 20878

Tel (301) 258-4715
Fax (301) 258-4620
Email: tim.meigs@pharma.novartis.com



GENETIC THERAPY, INC.
A Novartis Company

Fax

Attention Examiner Myron Hill, Art Unit 1648
Fax no. 703-308-4242
Number of pages 6
Date October 31, 2002


FAX RECEIVED
NOV 01 2002
GROUP 1600

RE: Application No. 09/870,203
Confirmation No. 7861


Dear Examiner Hill,

Included herewith for filing in App. No. 09/870,203 is a Reply to the Restriction/Election Requirement mailed July 31, 2002, and Preliminary Amendment. Also included is a petition for a Two-Month Extension of Time.

Respectfully submitted,


J. Timothy Meigs
Reg. No. 38,241
Attorney for Applicant

PRIVILEGED AND CONFIDENTIAL information intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original to us at the address above via the U.S. Mail. Thank you.

 **NOVARTIS**

#10/A
11-6-02
mwCERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the
Patent Office Fax No. (703) 308-4242 on the date shown below.

J. Timothy Meigs
Type or Print Name

J. Timothy Meigs
Signature

Oct- 31, 2002
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hallenbeck et al.

App. No. 09/870,203

Filed: May 30, 2001

For: **Adenovirus Particles With Mutagenized
Fiber Proteins**

Confirmation No. 7861

Art Unit: 1648

Examiner: Myron Hill

Atty Docket: 4-31452A

REPLY TO RESTRICTION/ELECTION REQUIREMENT
AND
PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction/Election Requirement dated July 31, 2002, Applicant hereby elects the invention set forth in Group I (claims 1-7 and 33-36) with traverse.

An Extension of Time for two months is hereby requested pursuant to 37 C.F.R. §1.136(a). Please charge Deposit Account No. 19-0134 (in the name of Novartis Pharmaceutical Corporation) in the amount of \$400.00 for payment of the extension fee. The Commissioner is authorized to charge any additional fees under 37 C.F.R. §1.17 that may be required, or credit any overpayment, to Novartis Pharmaceutical Corporation's Deposit Account No. 19-0134.

11/06/2002 MWILLARI 00000002 190134 09870203

01 FC:1252 400.00 CH